Clinuvel Pharmaceuticals (CUV) Price & Analysis

Compare

103 Followers

CUV Stock Chart & Stats

AU$11.08

-AU$0.31(-2.63%)

At close: Jan 09 4:00 PM EST

AU$11.08

-AU$0.31(-2.63%)

Day’s Range― - ―

52-Week RangeAU$9.41 - AU$14.00

Previous CloseN/A

Volume193.84K

Average Volume (3M)97.23K

Market Cap

AU$532.13M

Enterprise ValueAU$308.37M

Total Cash (Recent Filing)AU$224.11M

Total Debt (Recent Filing)AU$528.53K

Price to Earnings (P/E)14.7

Beta0.50

Next Earnings

Feb 24, 2026

EPS Estimate

0.29

Next Dividend Ex-DateN/A

Dividend Yield0.38%

Share Statistics

EPS (TTM)0.44

Shares Outstanding50,200,740

10 Day Avg. Volume118,433

30 Day Avg. Volume97,231

Financial Highlights & Ratios

PEG Ratio0.00

Price to Book (P/B)2.16

Price to Sales (P/S)5.47

P/FCF Ratio12.74

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Balance Sheet StrengthVery low leverage and a strong equity base provide durable financial flexibility. This reduces refinancing and solvency risk, enables sustained R&D and commercialization spending, and supports long-term operations during clinical or reimbursement delays without eroding shareholder value.

Cash Reserves & Debt-free StatusSubstantial cash growth and a decades-long debt-free record give the company runway to fund trials, manufacturing scale-up, and U.S. expansion without relying on volatile equity or debt markets. This strengthens resilience to setbacks and underpins consistent dividend policy.

Clinical Progress & U.S. ExpansionA fully recruited Phase III trial and active manufacturing initiatives broaden the long-term commercial pipeline beyond the flagship product. Combined with growing trained U.S. sites, this materially improves future revenue diversification and sustainable market penetration if trials succeed and approvals follow.

Bears Say

Regulatory SetbackFailure to secure EMA support for adolescent label expansion curtails a clear route to enlarge addressable market and delays revenue upside from younger patients. Prolonged regulatory uncertainty increases commercialization timelines and costs for alternative approval pathways.

Rising Operating ExpensesSustained increases in personnel and distribution costs raise the company’s fixed cost base. If revenue growth doesn’t accelerate commensurately, margin compression and variability in free cash flow could persist, limiting reinvestment capacity and dividend sustainability over the medium term.

Revenue ConcentrationHeavy reliance on a single flagship product concentrates commercial, regulatory, and reimbursement risk. While pipeline programs exist, they are not yet commercialized; a product-specific adverse event, pricing pressure, or reimbursement change could meaningfully impact revenue stability over the next several quarters.

Clinuvel Pharmaceuticals News

Clinuvel Flags Wide-Ranging Risks Ahead of Institutional Investor Meetings

An update from Clinuvel Pharmaceuticals ( ($AU:CUV) ) is now available. Clinuvel Pharmaceuticals has issued an update noting...

15d ago

Clinuvel Starts Preclinical Dosing of New Controlled-Release Peptide Platform VLRX-L

Clinuvel Pharmaceuticals ( ($AU:CUV) ) just unveiled an announcement. Clinuvel Pharmaceuticals has begun dosing in a new preclinical...

1M ago

Clinuvel Reports New Positive Vitiligo Data for SCENESSE® in Darker-Skinned Patients

The latest announcement is out from Clinuvel Pharmaceuticals ( ($AU:CUV) ). Clinuvel Pharmaceuticals has reported new clinical data...

1M ago

Clinuvel Pharmaceuticals Reports Lapse of 5,425 Performance Rights

Clinuvel Pharmaceuticals ( ($AU:CUV) ) has provided an update. Clinuvel Pharmaceuticals Limited, an Australian listed biopharmaceutical company trading...

2M ago

Clinuvel Files U.S. GAAP 20-F as It Targets Nasdaq ADR Uplisting

Clinuvel Pharmaceuticals ( ($AU:CUV) ) just unveiled an announcement. Clinuvel Pharmaceuticals has filed a draft registration statement, including...

2M ago

CLINUVEL Expands Singapore RD&I Centre for Advanced Peptide Therapies

An announcement from Clinuvel Pharmaceuticals ( ($AU:CUV) ) is now available. CLINUVEL PHARMACEUTICALS LTD has announced a significant...

2M ago

CLINUVEL Targets Mid-2026 for European Filing of NEURACTHEL® Instant

Clinuvel Pharmaceuticals ( ($AU:CUV) ) has issued an update. CLINUVEL Pharmaceuticals announced a significant milestone with the planned...

3M ago

Clinuvel Pharmaceuticals Addresses Operational Challenges and Strategic Focus

The latest update is out from Clinuvel Pharmaceuticals ( ($AU:CUV) ). Clinuvel Pharmaceuticals has issued a release highlighting...

3M ago

CLINUVEL Faces Potential Delays in Nasdaq Uplisting Amid U.S. Government Shutdown

Clinuvel Pharmaceuticals ( ($AU:CUV) ) just unveiled an update. CLINUVEL Pharmaceuticals announced potential delays in its plan to...

4M ago

Clinuvel Pharmaceuticals Emphasizes Strategic Cash Utilization for Sustained Growth

An announcement from Clinuvel Pharmaceuticals ( ($AU:CUV) ) is now available. In a departure from traditional presentations, Clinuvel...

4M ago

CUV FAQ

What was Clinuvel Pharmaceuticals Limited’s price range in the past 12 months?

Clinuvel Pharmaceuticals Limited lowest share price was AU$9.41 and its highest was AU$14.00 in the past 12 months.

What is Clinuvel Pharmaceuticals Limited’s market cap?

Clinuvel Pharmaceuticals Limited’s market cap is AU$532.13M.

When is Clinuvel Pharmaceuticals Limited’s upcoming earnings report date?

Clinuvel Pharmaceuticals Limited’s upcoming earnings report date is Feb 24, 2026 which is in 8 days.

How were Clinuvel Pharmaceuticals Limited’s earnings last quarter?

Clinuvel Pharmaceuticals Limited released its earnings results on Aug 27, 2025. The company reported AU$0.439 earnings per share for the quarter, beating the consensus estimate of AU$0.28 by AU$0.159.

Is Clinuvel Pharmaceuticals Limited overvalued?

According to Wall Street analysts Clinuvel Pharmaceuticals Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Clinuvel Pharmaceuticals Limited pay dividends?

Clinuvel Pharmaceuticals Limited pays a Annually dividend of AU$0.05 which represents an annual dividend yield of 0.38%. See more information on Clinuvel Pharmaceuticals Limited dividends here

What is Clinuvel Pharmaceuticals Limited’s EPS estimate?

Clinuvel Pharmaceuticals Limited’s EPS estimate is 0.29.

How many shares outstanding does Clinuvel Pharmaceuticals Limited have?

Clinuvel Pharmaceuticals Limited has 50,200,740 shares outstanding.

What happened to Clinuvel Pharmaceuticals Limited’s price movement after its last earnings report?

Clinuvel Pharmaceuticals Limited reported an EPS of AU$0.439 in its last earnings report, beating expectations of AU$0.28. Following the earnings report the stock price went down -7.527%.

Which hedge fund is a major shareholder of Clinuvel Pharmaceuticals Limited?

Currently, no hedge funds are holding shares in AU:CUV

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Clinuvel Pharmaceuticals Stock Smart Score

Neutral

Blogger Sentiment

Bullish

AU:CUV Sentiment 70%
Sector Average 69%

Technicals

Fundamentals

Return on Equity

15.90%

Trailing 12-Months

Asset Growth

15.26%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Clinuvel Pharmaceuticals Limited

Clinuvel Pharmaceuticals Limited is a biopharmaceutical company focused on developing and commercializing innovative therapies for patients with severe skin disorders and other related conditions. The company operates primarily in the healthcare sector, with a strong emphasis on photoprotection and skin repair. Its flagship product, SCENESSE (afamelanotide), is designed to provide protection against the harmful effects of ultraviolet (UV) light and is particularly beneficial for individuals with erythropoietic protoporphyria (EPP), a rare genetic disease that causes extreme sensitivity to sunlight.